Gene Expression Profiling in Breast Cancer
|
|
- Blaze Sutton
- 7 years ago
- Views:
Transcription
1 Molecular assays can assist in choosing therapy and predicting outcomes in almost 50% of women with breast cancer. Nick Patten. Martha (detail). Oil on panel, 22" 28". Gene Expression Profiling in Breast Cancer Kiran Turaga, MD, MPH, Geza Acs, MD, PhD, and Christine Laronga, MD, FACS Background: Breast cancer is a heterogeneous group of different tumor subtypes that vary in prognosis and response to therapy. This heterogeneity has spawned an era of molecular assays striving to classify and thus predict outcome, thereby guiding the future in targeted personalized treatment strategies. Methods: This article provides an overview of the development and application of molecular assays as applied to breast cancer. Differences in the technology used for these tests as well as scientific evidence supporting the validity of the gene expression profile are discussed. Examples of the clinical applicability of these assays are provided, but these represent only a fraction of the potential uses yet to be discovered. A comparison of the three most commonly used assays is included. Results: Molecular assays have provided new genetic approaches to unravel the complexities of clinical specimens relevant to breast cancer treatment planning and assessment of outcome. In particular, on a molecular level specific to the woman s tumor, these assays allow a prediction of outcome (prognosis) in terms of low and high risk for the future development of distant metastatic disease. Additionally, one assay, Oncotype DX (Genomic Health Inc, Redwood City, CA), allows for the prediction of benefit of the addition of chemotherapy to hormone therapy alone. Conclusions: While incorporation of molecular assays into the treatment planning strategy of breast cancer continues to be a work in progress, this approach is evolving quickly due to strong scientific evidence to become standard of practice in the near future. The possibilities of these assays in terms of clinical investigation are limitless, but currently their general applicability is limited to less than half of the population of women presenting with breast cancer. Introduction Breast cancer is slowly being recognized as an umbrella designation of different tumor subtypes that differ in their prognosis and their responses to therapy. 1 Despite the significant heterogeneity, substantive ad vances have From the Comprehensive Breast Program, Department of Women s Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida. Submitted September 29, 2009; accepted March 10, Address correspondence to Christine Laronga, MD, FACS, Comprehensive Breast Program, Department of Women s Oncology, MCC BRPROG, Moffitt Cancer Center, Magnolia Drive, Tampa, FL Christine.Laronga@moffitt.org Dr Laronga is on the speakers bureau for Genomic Health, Inc. The other authors report no significant relationship with the companies/organizations whose products or services may be referenced in this article. been made over the past decade in the care of patients with breast cancer. For instance, targeted therapies such as hormone therapy for estrogen receptor (ER) expression and the use of trastuzumab for inhibition of HER2 signaling have contributed significantly to these advances. It has become clear that the traditionally used one size fits all approach has important limitations. These include (1) drugs may be administered at suboptimal doses to drug-resistant patients, (2) tumors highly responsive to a medication may receive additional unnecessary treatments, and (3) accumulation of treatments may not be cost effective if we could identify the most responsive subset of patients. 2 Utilizing molecular predictors has been cited as a cost-effective way of directing targeted therapies to vulnerable populations with significant cost savings of $920,000 in a cohort of July 2010, Vol. 17, No. 3 Cancer Control 177
2 260 node-negative, ER-positive breast cancer patients. 3 The heterogeneity of outcome and drug sensitivity continues to drive the discovery of a second generation of molecular predictors. These have been developed using DNA-based arrays or reverse transcriptase-polymerase chain reaction (RT-PCR) and are expected to improve the quality of care for patients with breast cancer. We discuss briefly the current gene expression profiling tests, the validity of these tests, and the future of the second generation of gene expression profiling tests. Background Gene expression is a measure of a gene s activity, which is determined by the number of times it is transcribed into mrna and finally by the protein it encodes. A snapshot of a tissue s global gene activity (or expression) is captured by DNA microarray technology or RT- PCR and is called a transcriptome. Lists of genes associated with prognoses, responses to various treatments or phenotypes, are called gene profiles or gene signatures. The four major test platforms used for detecting gene profiles are immunohistochemistry (IHC), fluorescent in situ hybridization (FISH), quantitative reverse transcriptase polymerase chain reaction (qrt-pcr), and cdna microarray (quantitative cdna detection). While the former two platforms are semiquantitative and well established for detection of ER and HER2 status at low costs, the latter two are quantitative methods that require complex statistical methods to avoid false discovery. These two methodologies provide highly standardized and reproducible outcomes of uncertain prognostic value at this point. In addition, IHC has the advantage of directly measuring protein expression, not just mrna copy numbers, and it provides a visualization of the difference of protein localization and modification, which gene profiling cannot. All platforms can use formalin-fixed, paraffin-embedded tissues except cdna microarray, which preferentially uses freshfrozen samples only. Fresh-frozen tissues are expensive to obtain and store, require advance planning with informed consent at the time of surgery, and are currently not linked to any long-term outcome data, thus limiting their widespread applicability to the population at large. Currently available breast cancer molecular predictors based on the aforementioned platforms are listed in Table Predicting Disease Outcomes Below we discuss the three most commonly used gene profiling tests: Oncotype DX (Genomic Health Inc, Redwood City, CA), MammaPrint (Agendia Inc, Huntington Beach, CA), and HOXB13/IL17BR (H/I) expression ratio (Theros H/I; biotheranostics, San Diego, CA). Oncotype DX Assay Due to limitations aforementioned with fresh-frozen tissues, investigators sought to develop a genomic molecular assay using readily available and inexpensive paraffin-embedded tissue tumor blocks. After mastering the technique of reliably and reproducibly extracting mea- Table 1. Selected Molecular Predictor Tests Based on Platform Platform Assay Properties IHC ProEx Br 4 5-antibody panel/gene assay, overexpression of 2 linked to disease relapse Mammostrat 5 5-antibody panel/gene assay used to classify ER+, LN tumors treated with tamoxifen into high-, medium-, and low-risk groups FISH exagenbc 6 3 genes for ER+ tumors and 3 different genes for ER tumors, high-risk patients linked to high recurrence rates RT-PCR Oncotype DX 7 21-gene assay originally validated in ER+, LN patients to predict recurrence score and benefit of adjuvant chemotherapy. Now also validated in LN+, ER+ breast cancer H/I 8 6-gene assay, originally described as a ratio of 2 genes; prediction of recurrence in both tamoxifen-treated and -untreated patients, although effect in treated patients is challenged Celera metastasis score 9 14-gene assay test predicts 3.5-fold difference in risk between patients at the top and bottom quintiles of disease risk Breast bioclassifier classifier genes, 5 control genes; identifies patients independent of ER status who might benefit from chemotherapy DNA Microarray MammaPrint gene assay used for patients aged < 55 yrs with LN cancer (Amsterdam signature) Rotterdam signature gene assay used for patients with LN cancer independent of hormone status Invasiveness gene signature gene assay used irrespective of node and hormone receptor status Nuvoselect gene assay for chemotherapy response to T-FAC; 200-gene assay for hormone therapy Cytochrome P450 CYP2D gene assay that predicts benefit of aromatase inhibitors to tamoxifen in patients with ER+ disease Gene expression grade index gene assay that correlates with histological grade and classifies grade II patients into low- and high-risk recurrence groups T-FAC = paclitaxel, 5-fluorouracil, doxorubicin, and cyclophosphamide, LN = lymph node, ER = estrogen receptor. 178 Cancer Control July 2010, Vol. 17, No. 3
3 surable RNA from numerous tumor blocks of varying durations of storage, the developers panned the world s literature looking for candidate genes that have been linked to breast cancer and identified 250 candidate genes. A total of 447 archival tumor blocks were then retrieved from three separate clinical trials that reported data on long-term outcomes: the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-20 study (233 patients), the single-site study at Rush Presbyterian-St Luke s Hospital (78 patients), and the single-site study at Providence St Joseph s Hospital (136 patients). These tumor blocks were assayed for all 250 genes, with the result that all 250 genes could be measured reliably and reproducibly. The next step was to link combinations of expression of these genes with the outcomes data in such a way as to be able to separate patients into three cohorts: low-risk, intermediate-risk, and high-risk for the development of distant metastatic disease at 10 years. The combination of 16 cancer-related genes and five reference genes using a continuous variable algorithm allowed for the most informative separation into risk categories. In order to validate that this was the correct combination of genes, tumor blocks were retrieved from two additional prospective clinical trials in breast cancer patients with ER-positive, lymph node-negative disease (NSABP B-14 and Kaiser Permanente), and similar results were found. Of the multiple genes and their pathways, the most influential are genes related to the cell proliferation group (such as Ki-67), the ER expression and related genes (ER group), and the HER2 expression and related genes (HER2 group). Thus, low levels of ER and high levels of proliferation genes and/or HER2 predict a higher risk of recurrence. A recurrence score is generated on a continuum from 0 to 100 and further subdivides patients into low score (< 18), intermediate score (> 18 and < 30), or high score ( 31). 7 The score is then translated into a percent risk for the development of distant metastatic disease at 10 years, with a score of 18 signifying 10% risk and a score of 31 equal to 20% risk. The overall analytical validity of the Oncotype DX assay varies from 67.7% to 98.9%. 1 Four initial studies have assessed the validity of the Oncotype DX. 7,17-19 Studies on the NSABP B-14 cohort from the tamoxifen-treated arm of ER-positive, lymph node-negative patients revealed three risk categories with univariate actuarial recurrence risks of 7% (low), 14% (intermediate), and 31% (high). These are consistent with the overall study s 10-year disease-free survival rate of 85%. A 50-point change in the recurrence Table 2. Patient Reclassification by Gene Expression Testing With Oncotype DX Comparator Risk Group Patients in Risk 10-Year Risk for Group, n (%) Distant Relapse, % Oncotype DX Risk Group Patients in Risk 10-Year Risk for Group, n (%) Distant Relapse, % St Gallen expert criteria Low 38 (72) 0 Low 53 (8) 5 Medium 12 (22) 18 High 3 (6) 43 Low 134 (60) 5 Medium 222 (33) 9 Medium 51 (23) 6 High 37 (17) 21 Low 166 (42) 8 High 393 (59) 18 Medium 86 (22) 18 High 141 (36) National Comprehensive Cancer Network guidelines Low 38 (72) 0 Low 53 (8) 5 Medium 12 (22) 18 High 3 (6) 43 Low 300 (49) 8 High 615 (92) 15 Medium 137 (22) 14 High 178 (29) 30 Adjuvant! Online criteria Low 354 (53) 8 Low 216 (61) 6 Medium to high 138 (39) 13 Low 122 (39) 9 Medium to high 314 (47) 22 Medium to high 192 (61) 31 ANNALS OF INTERNAL MEDICINE. ONLINE by Luigi Marchionni, Renee F. Wilson, Antonio C. Wolff, Spyridon Marinopoulos, Giovanni Parmigiani, Eric B. Bass, and Steven N. Goodman. Copyright 2010 by AMERICAN COLLEGE OF PHYSICIANS - JOURNALS. Reproduced with permission of AMERICAN COL- LEGE OF PHYSICIANS - JOURNALS in the format Journal via Copyright Clearance Center. July 2010, Vol. 17, No. 3 Cancer Control 179
4 score was the single most important prognostic marker in the cohort (hazard ratio = 2.8; 95% confidence interval [CI], ). A study by Glas et al 20 revealed similar 10-year probability of death of 2.8%, 11%, and 16% in the low-, intermediate-, and high-risk groups, respectively, in a cohort of 165 ER-positive tamoxifen-treated patients. The prognostic value persisted after stratification by tumor grade and disease stage. Conversely, a small study revealed no predictive value of the recurrence score in patients who did not receive either tamoxifen or chemotherapy. 19 A recent systematic review reported the comparison of the performance of the Oncotype DX in the presence of stratification of other commonly used risk factors (Table 2). 1 It appears that in the presence of conventional risk predictors for breast cancer, molecular prognostics using the Oncotype DX changed the recurrence rate for half of the 92% of high-risk candidates by the National Comprehensive Cancer Network (NCCN) guidelines (2004) to low risk with a 10-year relapse risk of 7% (95% CI, 4% 11%). Thus, the use of Oncotype DX appears to better predict outcome than conventional predictors. Another facet of the Oncotype DX assay is the prediction of benefit of adjuvant chemotherapy. Several studies, including the original study NSABP B-20, showed that patients with a low-risk recurrence score (50% of the study cohort) had no benefit in terms of distant metastatic disease or survival with the addition of chemotherapy over hormone therapy alone. 21 Criticisms of this assay s utility initially centered on the fact that the validation studies used tamoxifen (not the modern aromatase inhibitors) and antiquated chemotherapy such as cyclophosphamide, methotrexate, and 5-fluorouracil (CMF). Recent studies presented at national and international breast cancer symposia have addressed these concerns but have not yet been published. One study used the tumor blocks from the ATAC trial comparing an aromatase inhibitor to tamoxifen (Arimidex, tamoxifen, alone or in combination) for the treatment of ER-positive breast cancer (patients Table 3. Kaplan-Meier Analysis of Survival Stratified by MammaPrint and Adjuvant! Online MammaPrint Prognosis Group Adjuvant! Online Risk Group Low Risk High Risk Good Patients, n year overall survival 0.88 ( ) 0.89 ( ) (95% CI) Poor Patients, n year overall survival 0.69 ( ) 0.69 ( ) (95% CI) ANNALS OF INTERNAL MEDICINE. ONLINE by Luigi Marchionni, Renee F. Wilson, Antonio C. Wolff, Spyridon Marinopoulos, Giovanni Parmigiani, Eric B. Bass, and Steven N. Goodman. Copyright 2010 by AMERICAN COLLEGE OF PHYSICIANS - JOURNALS. Reproduced with permission of AMERICAN COLLEGE OF PHYSICIANS - JOURNALS in the format Journal via Copyright Clearance Center. were lymph node-positive or -negative), and the Oncotype DX assay performed equally well with the aromatase inhibitor. 22 The ATAC trial was also important in extending the applicability of the assay to lymph nodepositive patients. 23 Although lymph node-positive patients overall do not fare as well as lymph node-positive patients, the Oncotype DX assay can assign a valid recurrence score and demonstrate the benefit of adjuvant chemotherapy in the high-risk category. 22 The data supporting the use of Oncotype DX assay in the lymph node-positive patient are rapidly amassing, but use of this assay in this setting has not yet gained widespread acceptance. MammaPrint Assay Following efforts to identify prognostic markers, MammaPrint was developed to seek gene expression profiles related to breast cancer by using fresh-frozen tissue. MammaPrint s top-down approach used a comprehensive search of marker genes among all candidate genes irrespective of the biology. Thus, a 70-gene signature was derived from more than 25,000 candidate genes on a cdna array. The original data set used for the test included 78 patients less than 55 years of age with invasive tumors < 5 cm in diameter, ER-positive or -negative disease, and the outcome recorded as distant recurrence at 5 years. Patients are classified based on correlation with a good-prognosis gene expression profile; a coefficient of greater than 0.4 is classified as good prognosis. In a validation study of 295 patients with stage I and II breast cancer, those with a good prognosis had dramatically better 5-year (95% vs 61%) and 10-year (85% vs 51%) recurrence-free survival rates. 11 Although the validation study included 61 of the 78 patients originally used for development of the prognostic signature, sophisticated statistical methods were employed including cross-validated classification to predict outcome among patients. Results excluding the 61 patients were presented in the study. An independent validation multicenter study of 302 patients not treated with tamoxifen or chemotherapy revealed that MammaPrint provided reclassification of patients in high-risk groups (hazard ratio for distant recurrence was 4.6 vs 2.1 for the low-risk groups). This demonstrated the power of discrimination among patients conventionally classified as high-risk patients (Table 3). 24 H/I Assay In a top-down approach similar to that used with MammaPrint, two genes were identified among 22,000 genes in 60 ER-positive patients treated with tamoxifen in a study published by Ma et al. 8 Expression of homeobox HOXB13 was positively correlated with recurrence, while interleukin 17B receptor gene (IL17BR) was negatively correlated with recurrence. This test essentially examines the ratio of these two genes. Initial validation studies by different authors revealed a prediction effect of none to modest, but the stage of disease was more advanced in these studies than in the 180 Cancer Control July 2010, Vol. 17, No. 3
5 original sample. 25,26 Subsequently, a large validation study was undertaken including 852 patients with stage I and II breast cancer, using a different method than originally described by the authors. 27 In this analysis, the ratio of H/I was predictive in node-negative, ER-positive disease, with an adjusted hazard ratio of 3.9 irrespective of treatment. Subsequent validation studies 28,29 suggested that HOXB13 was associated with tamoxifen resistance while IL17BR was independently associated with prognosis. Both studies varied from the protocol in the original study in the populations to which these were applied. Comparison of Signatures Fan et al 30 used the data from 295 patients with stage I and II breast cancer who were originally used to develop the 70-gene signature of MammaPrint to determine the recurrence score by Oncotype DX and the H/I test. Both of these were estimated from gene expression data and not from RT-PCR, and the test was expected to favor the MammaPrint test since it was the data set that was used to develop the signature. MammaPrint and the derived recurrence score from the Oncotype DX predicted overall and disease-free survival, but the H/I test did not (hazard ratio = 1). This may have been in part because the measurement of the gene ratio may have been flawed. 31 On comparison of the intermediate- and high-risk groups from the Oncotype DX to the poor prognosis group of the MammaPrint, the agreement was 81% (239 of 295). 1 Correlation was also noted among the ER-positive subset. As noted earlier, Oncotype DX is the only test to have been studied in the prediction of response. Paik et al 21 found that the benefit of chemotherapy for 651 patients with ER-positive, lymph node-negative disease was highest in those with a high recurrence score, ie, relative risk of 0.26 (95% CI, ). Additionally, in the neoadjuvant setting, three studies have investigated the use of Oncotype DX in predicting response to chemotherapy Two of them found that recurrence score (high) correlated with clinical response, while one study showed no such association The different features of the Oncotype DX, MammaPrint, and H/I tests are summarized in Table 4. Continuing Research The use of gene signatures has considerable potential for improving prognostic and therapeutic prediction. While the exact role of these genes is not understood, they may indeed be markers of already detected clinically relevant markers. The relevance of molecular markers would be in the reclassification of patients into risk strata after being classified by conventional methods such as Adjuvant! Online ( or the NCCN risk criteria. In addition, marketed tests do not reproduce the exact results from the gene signature; comparison of the MammaPrint gene signature to the marketed test revealed a 9% misclassification. Hence, information from genetic signature tests needs to be treated with caution and the tests need to be applied appropriately. It is now clear that breast cancer may be considered a molecularly heterogeneous disease, and genetic signatures should probably focus on more homogeneous test groups such as those used by the Oncotype DX test. In addition, treatment-specific signatures need to be developed. To date, the Oncotype DX is the only test that has shown benefit from the addition of chemotherapy to hormone therapy in high-risk groups. Two ongoing trials are focusing on genetic profiling of tumors: the TAILORx (Trial Assigning Individualized Options for Treatment trial) and the MINDACT (Microarray in Node Negative Disease May Avoid Chemotherapy trial). The TAILORx trial stratifies patients into three groups, using the recurrence score on Oncotype DX. Patients in group 1, with a score < 10, receive hormonal treatment only. Patients in group 2, with a score of > 25, receive combination chemotherapy and hormonal Table 4. Comparison of Commonly Used Breast Cancer Signatures Used for Prediction Variable Oncotype DX MammaPrint H/I Test Development of signature From 250 candidate genes in From candidate set of 25,000 genes From candidate set of 22,000 genes 447 patients in 78 patients in 60 patients Nature of signature 21 genes 70 genes 2 genes; now 6 genes Nature of test subjects Stage I and II breast cancer Stage I and II breast cancer ER+ breast cancer patients, ER+ LN treatment with tamoxifen LN < 55 yrs of age Receiving tamoxifen therapy < 5 cm tumors Outcome Distant relapse-free survival Distant metastasis as first Disease-free survival, relapse-free at 10 yrs relapse event at 5 yrs survival at 5 yrs Test results Recurrence score: Correlation coefficient: Ratio of H/I presented after Low < 18 > 0.4: good prognosis normalization of ratio, Intermediate : poor prognosis presented as hazard ratio High 30 Cost of test $3,978 $4,200 $1,400 Sample characteristics Formalin-fixed, paraffin- Fresh-frozen tumor samples or tissues Formalin-fixed, paraffinembedded tissues collected into RNA preservative embedded tissues July 2010, Vol. 17, No. 3 Cancer Control 181
6 therapy. Patients in group 3, with a score ranging from 11 to 25, are randomly assigned to receive either combination chemotherapy and hormonal therapy or hormonal therapy alone. The MINDACT trial is a multicenter trial comparing MammaPrint to Adjuvant! Online in patient selection for chemotherapy in node-negative disease. The data from these trials will determine the power of these signatures in reclassifying patients after conventional risk classification. Conclusions and Future Directions Several concepts under investigation today may change how gene prediction is performed. Recent discoveries of embryonic stem cell identity in poorly differentiated tumors suggest that cancer prediction using embryonic stem cell signatures may be an important direction for further research. 35 At this point, significant information gleaned from molecular tests needs to be tempered with clinical judgment and applied in the appropriate setting. The extent of the benefit offered by molecular assays, the role of these tests in clinical decision-making, and their impact on cost effectiveness must be rigorously evaluated prior to widespread use. References 1. Marchionni L, Wilson RF, Wolff AC, et al. Systematic review: gene expression profiling assays in early-stage breast cancer. Ann Intern Med. 2008;148(5): Desmedt C, Ruíz-García E, André F. Gene expression predictors in breast cancer: current status, limitations and perspectives. Eur J Cancer. 2008;44(18): Liang H, Brufsky AM, Lembersky BB, et al. A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center. Presented at the 30th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 13-16, Abstract Whitehead CM, Nelson R, Hudson P, et al. Selection and optimization of a panel of early stage breast cancer prognostic molecular markers. Mod Pathol. 2004;17:50A. 5. Ring BZ, Seitz RS, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(19): Davis LM, Harris C, Tang L, et al. Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. J Mol Diagn. 2007;9(3): Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27): Ma XJ, Wang Z, Ryan PD, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004;5(6): Garber K. Genomic medicine. Gene expression tests foretell breast cancerʼs future. Science. 2004;303(5665): Perreard L, Fan C, Quackenbush JF, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT- PCR assay. Breast Cancer Res. 2006;8(2):R van de Vijver MJ, He YD, vanʼt Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347 (25): Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;65(9460): Liu R, Wang X, Chen GY, et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med. 2007;356(3): Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004; 22(12): Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1): Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98(4): Cobleigh MA, Tabesh B, Bitterman P, et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res. 2005;11(24 pt 1): Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph nodenegative patients. Breast Cancer Res. 2006;8(3):R Esteva FJ, Sahin AA, Cristofanilli M, et al. Prognostic role of a multigene reverse transcriptase-pcr assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res. 2005; 11(9): Glas AM, Floore A, Delahaye LJ, et al. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics. 2006;7: Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemo - therapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23): Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1): Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 yearsʼ adjuvant treatment for breast cancer. Lancet. 2005;365(9453): Buyse M, Loi S, vanʼt Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006;98(17): Reid JF, Lusa L, De Cecco L, et al. Limits of predictive models using microarray data for breast cancer clinical treatment outcome. J Natl Cancer Inst. 2005;97(12): Goetz MP, Suman VJ, Ingle JN, et al. A two-gene expression ratio of homeobox 13 and interleukin-17b receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006; 12(7 Pt 1): Ma XJ, Hilsenbeck SG, Wang W, et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol. 2006;24(28): Jansen MP, Sieuwerts AM, Look MP, et al. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study. J Clin Oncol. 2007;25(6): Jerevall PL, Brommesson S, Strand C, et al. Exploring the two-gene ratio in breast cancer: independent roles for HOXB13 and IL17BR in prediction of clinical outcome. Breast Cancer Res Treat. 2008;107(2): Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355(6): Goetz MP, Ingle JN, Couch FJ. Gene-expression-based predictors for breast cancer. N Engl J Med. 2007;356(7):752; author reply Mina L, Soule SE, Badve S, et al. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat. 2007;103(2): Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23(29): Chang JC, Makris A, Gutierrez MC, et al. Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat. 2008;108(2): Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5): Cancer Control July 2010, Vol. 17, No. 3
One of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationDescription of Procedure or Service. assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer 11/2004 3/2015 3/2016 3/2015
Corporate Medical Policy Assays of Genetic Expression to Determine Prognosis of Breast File Name: Origination: Last CAP Review: Next CAP Review: Last Review: assays_of_genetic_expression_to_determine_prognosis_of_breast_cancer
More informationHow To Use A Breast Cancer Test To Help You Choose Chemotherapy
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat Issued: September
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationPrognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee
Prognostic and Predictive Factors in Breast Cancer Kyle T. Bradley, MD, MS CAP Cancer Committee Breast cancer is the most common malignant tumor in American women and is second only to lung cancer as a
More informationAIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY
AIDS IN IDENTIFYING CANDIDATES FOR HER2-TARGETED THERAPY THE HERMARK BREAST CANCER ASSAY HERmark is based on our proprietary VeraTag technology that precisely quantifies HER2 proteins and protein complexes
More informationBreast Cancer. Abstract. Keywords. Development of the 21-gene Assay Oncotype DX
Evolution of the 21-gene Assay Oncotype DX from an Experimental Assay to an Instrument Assisting in Risk Prediction and Optimisation of Treatment Decision-making in Early Breast Cancer Christian Jackisch,
More informationImpact of Gene Expression Profiling Tests on Breast Cancer Outcomes
Evidence Report/Technology Assessment Number 160 Impact of Gene Expression Profiling Tests on Breast Cancer Outcomes Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and
More informationClinical Policy Title: Gene expression profile testing for breast cancer
Clinical Policy Title: Gene expression profile testing for breast cancer Clinical Policy Number: 02.01.14 Effective Date: December 1, 2013 Initial Review Date: July 17, 2013 Most Recent Review Date: February
More informationHAVE YOU BEEN NEWLY DIAGNOSED with DCIS?
HAVE YOU BEEN NEWLY DIAGNOSED with DCIS? Jen D. Mother and volunteer. Diagnosed with DCIS breast cancer in 2012. An educational guide prepared by Genomic Health This guide is designed to educate women
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationLocal Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125)
Local Coverage Determination (LCD): MolDX: Breast Cancer Assay: Prosigna (L36125) Contractor Information Contractor Name Palmetto GBA LCD Information Document Information LCD ID L36125 Original ICD-9 LCD
More informationClinical Policy Title: Gene expression profile testing for breast cancer
Clinical Policy Title: Gene expression profile testing for breast cancer Clinical Policy Number: 02.01.14 Effective Date: December 1, 2013 Initial Review Date: July 17, 2013 Most Recent Review Date: April
More informationEffect of Chemotherapy for Luminal A Breast Cancer
Yonago Acta medica 2013;56:51 56 Original Article Effect of Chemotherapy for Luminal A Breast Cancer Naotaka Uchida,* Takako Suda and Kiyosuke Ishiguro *Clinic of Surgery, Tottori Prefectural Kosei Hospital,
More informationBreast Cancer Recurrence Assay (MammaPrint )
Harmony Behavioral Health, Inc. Harmony Behavioral Health of Florida, Inc. Harmony Health Plan of Illinois, Inc. HealthEase of Florida, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationPathologic Assessment Of The Breast And Axilla After Preoperative Therapy
Pathologic Assessment Of The Breast And Axilla After Preoperative Therapy W. Fraser Symmans, M.D. Associate Professor of Pathology UT M.D. Anderson Cancer Center Pathologic Complete Response (pcr) Proof
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationPositività per HER-2 nei carcinomi subcentimetrici
Positività per HER-2 nei carcinomi Antonella Ferro U.O. Oncologia Medica Trento Small Tumors Small tumors are becoming increasingly common with the use of mammography > screening Some of these tumors,
More informationPersonalized Predictive Medicine and Genomic Clinical Trials
Personalized Predictive Medicine and Genomic Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute http://brb.nci.nih.gov brb.nci.nih.gov Powerpoint presentations
More informationPharmacogenetic Activities in SWOG Breast Cancer
Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationGenomic Testing for Breast Cancer
Genomic Testing for Breast Cancer Why and How to Offer It 42 OI November December 2013 www.accc-cancer.org By James V. Pellicane, MD, FACS New technologies spread in medicine roughly the same way they
More informationHER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
More informationHER2 Testing in Breast Cancer
HER2 Testing in Breast Cancer GAIL H. VANCE, M.D. AGT MEETING JUNE 13, 2014 LOUISVILLE, KENTUCKY No Conflict of Interest to Report Human Epidermal Growth Factor Receptor 2-HER2 Human epidermal growth factor
More informationAssessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study
Sgroi et al. Breast Cancer Research (2016) 18:1 DOI 10.1186/s13058-015-0660-6 RESEARCH ARTICLE Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study
More informationAdjuvant Endocrine Therapy in Breast Cancer: 2015 Update
Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update Shannon Puhalla, MD Director, Breast Cancer Clinical Research Program Magee Womens Cancer Program University of Pittsburgh Cancer Institute Questions
More informationGleason Score. Oncotype DX GPS. identified for. about surveillance. time to get sophisticated
patient: MARK SMITH PSA 6.2 Gleason Score 6 Oncotype DX GPS 8 identified for active surveillance time to get sophisticated about surveillance Accurate prediction of prostate cancer risk is needed at the
More informationAbstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2
Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationNancy E. Davidson, MD Johns Hopkins University. Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationIndependent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens
Independent Validation of the Prognostic Gene Expression Ratio Test in Formalin Fixed, Paraffin Embedded (FFPE) Mesothelioma Tumor Tissue Specimens Assunta De Rienzo, Ph.D. 1, Robert W. Cook, Ph.D. 2,
More informationOpportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests
Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests James H. Doroshow, M.D. NCI Deputy Director for Clinical and Translational Research NCI Workshop: Evidence Needed
More informationMEDICAL POLICY EFFECTIVE DATE: 07/20/06 REVISED DATE: 10/18/07, 10/23/08, 10/29/09, 10/28/10, 03/17/11, 02/16/12, 01/17/13, 01/16/14
MEDICAL POLICY SUBJECT: HER-2 TESTING IN INVASIVE BREAST OR PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More informationGenetic Expression Assays for Breast Tumor Tissue Oncotype DX / MammaPrint
Genetic Expression Assays for Breast Tumor Tissue Oncotype DX / MammaPrint Policy Number: 2016M0008B Effective Date: February 1, 2016 Table of Contents: Page: Cross Reference Policy: POLICY DESCRIPTION
More informationReceptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?
Receptor conversion in distant breast cancer metastases Breast cancer metastases: A spitting image of their primary? Introduction Breast cancer is the leading cause of female cancer death worldwide (13,000
More informationPatient Guide to Breast Cancer Surgery and Treatment
Patient Guide to Breast Cancer Surgery and Treatment Coree H. Flight attendant and mother of 3. Diagnosed with invasive breast cancer in 2009. An educational guide prepared by Genomic Health This Is Your
More informationBREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I
BREAST CANCER UPDATE C H R I S S Z Y A R T O, D O G E N E S E E H E M A T O L O G Y O N C O L O G Y F L I N T, M I Overview Why is it important to understand breast cancer? Choosing wisely Appropriateness
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 5-year survival: an overview of the randomised trials Early Breast Cancer Trialists Collaborative Group (EBCTCG)*
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationAdjuvant Therapy with Trastuzumab
Adjuvant Therapy with Trastuzumab Hiroji Iwata, M.D. Department of Breast Oncology, Aichi Cancer Center Hospital Although this presentation includes information regarding pharmaceuticals (including products
More informationAnalysis of Prostate Cancer at Easter Connecticut Health Network Using Cancer Registry Data
The 2014 Cancer Program Annual Public Reporting of Outcomes/Annual Site Analysis Statistical Data from 2013 More than 70 percent of all newly diagnosed cancer patients are treated in the more than 1,500
More informationBioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy
BioPATH: A Study of Biomarker Profiles in Asia Pacific HER2 Breast Cancer Patients Treated with Lapatinib and Other Anti-HER2 Therapy Soonmyung Paik 1 ; Gyungyub Gong 2 ; Yap Yoon Sim 3 ; Tae- You Kim
More informationBasics and limitations of adjuvant online an internet based decision tool
Basics and limitations of adjuvant online an internet based decision tool J. Huober SAKK, Bern 31.10.2013 Univ.-Frauenklinik Ulm Integratives Tumorzentrum des Universitätsklinikums und der Medizinischen
More informationLa Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationBreast pathology directs systemic treatment. Dr. Sabine Linn Medical oncologist The Netherlands Cancer Institute Amsterdam The Netherlands
Breast pathology directs systemic treatment Dr. Sabine Linn Medical oncologist The Netherlands Cancer Institute Amsterdam The Netherlands Recent decline breast cancer mortality UK, US, NL, F; 35-69 years
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationAdjuvant treatment of breast cancer patients with trastuzumab
doi:10.2478/v10019-007-0020-y review Adjuvant treatment of breast cancer patients with trastuzumab Erika Matos, Tanja Čufer Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, Slovenia
More informationMolecular markers and clinical trial design parallels between oncology and rare diseases?
Molecular markers and clinical trial design parallels between oncology and rare diseases?, Harriet Sommer Institute for Medical Biometry and Statistics, University of Freiburg Medical Center 6. Forum Patientennahe
More informationHER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays
O R I G I N A L A R T I C L E HER2 overexpression of breast cancers in Hong Kong: prevalence and concordance between immunohistochemistry and in-situ hybridisation assays TK Yau H Sze Inda S Soong F Hioe
More informationPATHOLOGY. HercepTestTM. Product Information
PATHOLOGY HercepTestTM Product Information CLINICAL TRIALS HercepTest The First and Foremost Dako s pharmdx HercepTest was the first FDA-approved assay developed exclusively to aid physicians in identifying
More informationManagement of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
More informationYour Guide to the Breast Cancer Pathology Report
Your Guide to the Breast Cancer Pathology Report Developed for you by Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. The
More informationManagement of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
More informationManagement of ER+/HER2- Breast Cancer: New Options, New Insights, Coming Agents
Management of ER+/HER2- Breast Cancer: New Options, New Insights, Coming Agents P. Kelly Marcom, MD Associate Professor Co-Director Breast Cancer Clinical Research NCOA August 23, 2014 Off-Label Use Disclosure(s)
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationAccess to hormone receptor testing and other basic diagnostic pathology services in Colombia
Access to hormone receptor testing and other basic diagnostic pathology services in Colombia Dr Fernando Perry Clínica de seno y tejidos blandos Instituto Nacional de Cancerología de Colombia Breast cancer
More informationClinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents
Clinical Trial Designs for Incorporating Multiple Biomarkers in Combination Studies with Targeted Agents J. Jack Lee, Ph.D. Department of Biostatistics 3 Primary Goals for Clinical Trials Test safety and
More informationGentest für DCIS? SENOLOGIE update 2015 21. Mai 2015 Kongress-Eventzentrum LAKE SIDE Prof. Bernhard Pestalozzi, Klinik für Onkologie, USZ
Gentest für DCIS? SENOLOGIE update 2015 21. Mai 2015 Kongress-Eventzentrum LAKE SIDE Prof. Bernhard Pestalozzi, Klinik für Onkologie, USZ Gliederung Einführung: Multigen Profile OncotypeDX (21-gene score)
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationReview of Breast Cancer Clinical Trials Conducted by the National Surgical Adjuvant Breast Project
Surg Clin N Am 87 (2007) 279 305 Review of Breast Cancer Clinical Trials Conducted by the National Surgical Adjuvant Breast Project Lisa A. Newman, MD, MPH, FACS a, *, Eleftherios P. Mamounas, MD, MPH,
More informationNew Approval Mechanism for Breast Cancer using pathologic Complete Response
New Approval Mechanism for Breast Cancer using pathologic Complete Response Sandra M. Swain, MD, FACP Medical Director, Washington Cancer Institute MedStar Washington Hospital Center Professor of Medicine
More informationFlorida Breast Health Specialists Breast Cancer Information and Facts
Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to
More informationJ Clin Oncol 24:4888-4894. 2006 by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 30 OCTOBER 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationName of Policy: Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers
Name of Policy: Quantitative Assay for Measurement of HER2 Total Protein Expression and HER2 Dimers Policy #: 487 Latest Review Date: January 2016 Category: Laboratory Policy Grade: B Background/Definitions:
More informationMolecular Diagnostics in Thyroid Cancer
Disclosure Nothing to disclose Jonathan George, MD, MPH Assistant Professor Head and Neck Oncologic & Endocrine Surgery Molecular Diagnostics in Thyroid Cancer Current Practices & Future Trends UCSF Medical
More informationAn online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
Breast Cancer Res Treat (2010) :725 731 DOI 10.1007/s10549-009-0674-9 PRECLINICAL STUDY An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationEpidemiology. Breast Cancer Screening, Diagnosis, Biology and Long-Term Follow-Up EDUCATIONAL OBJECTIVES
Cancer Treatment Centers of America Breast Cancer: Screening, Diagnosis, Biology and Long-Term Follow-Up Presented to: Atlantic Regional Osteopathic Conference Presented by: Pamela Crilley, DO Date: April
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationPrognostic Significance of Progesterone Receptor Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
Published Ahead of Print on December 1, 212 as 1.12/JCO.212.43.4134 The latest version is at http://jco.ascopubs.org/cgi/doi/1.12/jco.212.43.4134 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationPATIENT SUBSETS WITH T1-T2, NODE-NEGATIVE BREAST CANCER AT HIGH LOCOREGIONAL RECURRENCE RISK AFTER MASTECTOMY
doi:10.1016/j.ijrobp.2004.09.013 Int. J. Radiation Oncology Biol. Phys., Vol. 62, No. 1, pp. 175 182, 2005 Copyright 2005 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/05/$ see front
More informationArticles. Early Breast Cancer Trialists Collaborative Group (EBCTCG)* www.thelancet.com Vol 366 December 17/24/31, 2005 2087
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials Early Breast Cancer Trialists
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationUse of Oncotype DX for guiding adjuvant chemotherapy decisions in early stage invasive breast cancer patients in Alberta
Use of Oncotype DX for guiding adjuvant chemotherapy decisions in early stage invasive breast cancer patients in Alberta A Health Technology Assessment Simrandeep K Tiwana, Alison Smith, Laura Leggett,
More informationA new score predicting the survival of patients with spinal cord compression from myeloma
A new score predicting the survival of patients with spinal cord compression from myeloma (1) Sarah Douglas, Department of Radiation Oncology, University of Lubeck, Germany; sarah_douglas@gmx.de (2) Steven
More informationA Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
The new england journal of medicine original article A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer Soonmyung Paik, M.D., Steven Shak, M.D., Gong Tang, Ph.D.,
More informationMale breast cancer - Wikipedia, the free encyclopedia
pagina 1 van 5 Male breast cancer From Wikipedia, the free encyclopedia Male breast cancer is a relatively rare cancer in men that originates from the breast. As it presents a similar pathology as female
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationBreast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis?
Breast cancer close to the nipple: Does this carry a higher risk ofaxillary node metastasesupon diagnosis? Erin I. Lewis, BUSM 2010 Cheri Nguyen, BUSM 2008 Priscilla Slanetz, M.D., MPH Al Ozonoff, Ph.d.
More informationDescription of Procedure or Service. gene_based_tests_for_screening_detection_or_management_of_prostate_cancer 4/2009 8/2015 8/2016 8/2015
Corporate Medical Policy Gene-Based Tests for Screening, Detection, and/or Management File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_based_tests_for_screening_detection_or_management_of_prostate_cancer
More informationControversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies
Annals of Oncology 15 (Supplement 4): iv23 iv29, 2004 doi:10.1093/annonc/mdh901 Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies V. D Hondt & M. Piccart
More informationComplimentary CME. Metastatic Breast Cancer: Monitoring Soluble HER2 Levels
Complimentary CME Metastatic Breast Cancer: Monitoring Soluble HER2 Levels Program Description HER2/neu-positive tumors account for approximately 20% of all breast cancers and these tumors carry poor prognosis.
More informationHow TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
More informationLocal control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins
The American Journal of Surgery 190 (2005) 521 525 George Peter s Award Winner Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins Heather R. MacDonald,
More informationProstate Cancer 2014
Prostate Cancer 2014 Eric A. Klein, M.D. Chairman Glickman Urological and Kidney Institute Professor of Surgery Cleveland Clinic Lerner College of Medicine Incidence rates, US Men Mortality Rates, US Men
More informationSTATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services
STATE OF MICHIGAN DEPARTMENT OF INSURANCE AND FINANCIAL SERVICES Before the Director of Insurance and Financial Services In the matter of: Petitioner, v Blue Care Network of Michigan, Respondent. File
More information